The Experts below are selected from a list of 1044 Experts worldwide ranked by ideXlab platform

Sudha Rajagopalan - One of the best experts on this subject based on the ideXlab platform.

  • Quantitative proteomics for identifying biomarkers for tuberculous meningitis
    Clinical Proteomics, 2012
    Co-Authors: Ghantasala S Sameer Kumar, H C Harsha, Abhilash K Venugopal, Santosh Renuse, Nandini A. Sahasrabuddhe, Anita Mahadevan, Harsh Pawar, Praveen Kumar, Rakesh Sharma, Sudha Rajagopalan
    Abstract:

    Introduction Tuberculous meningitis is a frequent extrapulmonary disease caused by Mycobacterium tuberculosis and is associated with high mortality rates and severe neurological sequelae. In an earlier study employing DNA microarrays, we had identified genes that were differentially expressed at the transcript level in human brain tissue from cases of tuberculous meningitis. In the current study, we used a quantitative proteomics approach to discover protein biomarkers for tuberculous meningitis. Methods To compare brain tissues from confirmed cased of tuberculous meningitis with uninfected brain tissue, we carried out quantitative protein expression profiling using iTRAQ labeling and LC-MS/MS analysis of SCX fractionated peptides on Agilent’s accurate mass QTOF mass spectrometer. Results and conclusions Through this approach, we identified both known and novel differentially regulated molecules. Those described previously included signal-regulatory protein alpha (SIRPA) and protein disulfide isomerase family A, member 6 (PDIA6), which have been shown to be overexpressed at the mRNA level in tuberculous meningitis. The novel overexpressed proteins identified in our study included amphiphysin (AMPH) and neurofascin (NFASC) while Ferritin Light Chain (FTL) was found to be downregulated in TBM. We validated amphiphysin, neurofascin and Ferritin Light Chain using immunohistochemistry which confirmed their differential expression in tuberculous meningitis. Overall, our data provides insights into the host response in tuberculous meningitis at the molecular level in addition to providing candidate diagnostic biomarkers for tuberculous meningitis.

  • Quantitative proteomics for identifying biomarkers for tuberculous meningitis
    Clinical proteomics, 2012
    Co-Authors: Ghantasala S Sameer Kumar, H C Harsha, Abhilash K Venugopal, Santosh Renuse, Nandini A. Sahasrabuddhe, Anita Mahadevan, Harsh Pawar, Praveen Kumar, Rakesh Sharma, Sudha Rajagopalan
    Abstract:

    Tuberculous meningitis is a frequent extrapulmonary disease caused by Mycobacterium tuberculosis and is associated with high mortality rates and severe neurological sequelae. In an earlier study employing DNA microarrays, we had identified genes that were differentially expressed at the transcript level in human brain tissue from cases of tuberculous meningitis. In the current study, we used a quantitative proteomics approach to discover protein biomarkers for tuberculous meningitis. To compare brain tissues from confirmed cased of tuberculous meningitis with uninfected brain tissue, we carried out quantitative protein expression profiling using iTRAQ labeling and LC-MS/MS analysis of SCX fractionated peptides on Agilent’s accurate mass QTOF mass spectrometer. Through this approach, we identified both known and novel differentially regulated molecules. Those described previously included signal-regulatory protein alpha (SIRPA) and protein disulfide isomerase family A, member 6 (PDIA6), which have been shown to be overexpressed at the mRNA level in tuberculous meningitis. The novel overexpressed proteins identified in our study included amphiphysin (AMPH) and neurofascin (NFASC) while Ferritin Light Chain (FTL) was found to be downregulated in TBM. We validated amphiphysin, neurofascin and Ferritin Light Chain using immunohistochemistry which confirmed their differential expression in tuberculous meningitis. Overall, our data provides insights into the host response in tuberculous meningitis at the molecular level in addition to providing candidate diagnostic biomarkers for tuberculous meningitis.

Mariepierre Joalland - One of the best experts on this subject based on the ideXlab platform.

  • validation of tumor associated macrophage Ferritin Light Chain as a prognostic biomarker in node negative breast cancer tumors a multicentric 2004 national phrc study
    International Journal of Cancer, 2012
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Catherine Guerincharbonnel, Jean Andre, Francoise Descotes, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR 5 1.30–95% CI: 1.10–1.50, p 5 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM. Sporadic breast cancer is obviously a disease where further molecular characterization is needed to improve patients monitoring because patients with the same diagnosis can have markedly different clinical outcome. Approximately 70% of patients with node-negative breast cancer will be metastasis-free 10 years after initial treatment without adjuvant chemotherapy, whereas 30% will develop metastatic relapse (MR). Traditional prognostic markers and indexes are not sufficient for precise risk-group discrimination in breast cancer. Current guidelines, such as St Gallen or NIH ones,

  • Validation of tumor‐associated macrophage Ferritin Light Chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study
    International journal of cancer, 2011
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Jean Andre, Francoise Descotes, Catherine Guérin-charbonnel, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR = 1.30-95% CI: 1.10-1.50, p = 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM.

  • surface enhanced laser desorption ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node negative breast cancer tumors
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Regine Deportefety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

  • Surface-enhanced laser desorption/ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node-negative breast cancer tumors.
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Régine Deporte-fety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

Delphine Loussouarn - One of the best experts on this subject based on the ideXlab platform.

  • validation of tumor associated macrophage Ferritin Light Chain as a prognostic biomarker in node negative breast cancer tumors a multicentric 2004 national phrc study
    International Journal of Cancer, 2012
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Catherine Guerincharbonnel, Jean Andre, Francoise Descotes, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR 5 1.30–95% CI: 1.10–1.50, p 5 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM. Sporadic breast cancer is obviously a disease where further molecular characterization is needed to improve patients monitoring because patients with the same diagnosis can have markedly different clinical outcome. Approximately 70% of patients with node-negative breast cancer will be metastasis-free 10 years after initial treatment without adjuvant chemotherapy, whereas 30% will develop metastatic relapse (MR). Traditional prognostic markers and indexes are not sufficient for precise risk-group discrimination in breast cancer. Current guidelines, such as St Gallen or NIH ones,

  • Validation of tumor‐associated macrophage Ferritin Light Chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study
    International journal of cancer, 2011
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Jean Andre, Francoise Descotes, Catherine Guérin-charbonnel, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR = 1.30-95% CI: 1.10-1.50, p = 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM.

  • surface enhanced laser desorption ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node negative breast cancer tumors
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Regine Deportefety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

  • Surface-enhanced laser desorption/ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node-negative breast cancer tumors.
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Régine Deporte-fety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

Mario Campone - One of the best experts on this subject based on the ideXlab platform.

  • validation of tumor associated macrophage Ferritin Light Chain as a prognostic biomarker in node negative breast cancer tumors a multicentric 2004 national phrc study
    International Journal of Cancer, 2012
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Catherine Guerincharbonnel, Jean Andre, Francoise Descotes, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR 5 1.30–95% CI: 1.10–1.50, p 5 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM. Sporadic breast cancer is obviously a disease where further molecular characterization is needed to improve patients monitoring because patients with the same diagnosis can have markedly different clinical outcome. Approximately 70% of patients with node-negative breast cancer will be metastasis-free 10 years after initial treatment without adjuvant chemotherapy, whereas 30% will develop metastatic relapse (MR). Traditional prognostic markers and indexes are not sufficient for precise risk-group discrimination in breast cancer. Current guidelines, such as St Gallen or NIH ones,

  • Validation of tumor‐associated macrophage Ferritin Light Chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study
    International journal of cancer, 2011
    Co-Authors: Pascal Jezequel, Mariepierre Joalland, Mario Campone, Delphine Loussouarn, Loic Campion, F Spyratos, Jean Andre, Francoise Descotes, Catherine Guérin-charbonnel, Catherine Grenot
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. Large screening of different biological compartments, such as the proteome, by means of high throughput techniques may greatly help scientists to find such markers. The present retrospective multicentric study included 268 node-negative breast cancer patients. We used a proteomic approach of SELDI-TOF-MS screening to identify differentially expressed cytosolic proteins with prognostic impact. The screening cohort was composed of 198 patients. Seventy supplementary patients were included for validation. Immunohistochemistry (IHC) and immunoassay (IA) were run to confirm the prognostic role of the marker identified by SELDI-TOF-MS screening. IHC was also used to explore links between selected marker and epithelial-mesenchymal transition (EMT)-like, proliferation and macrophage markers. Ferritin Light Chain (FTL) was identified as an independent prognostic marker (HR = 1.30-95% CI: 1.10-1.50, p = 0.001). Validation step by means of IHC and IA confirmed the prognostic value of FTL level. CD68 IHC showed that FTL was stored in tumor-associated macrophages (TAM), which exhibit an M2-like phenotype. We report here, first, the validation of FTL as a breast tumor prognostic biomarker in node-negative patients, and second, the fact that FTL is stored in TAM.

  • surface enhanced laser desorption ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node negative breast cancer tumors
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Regine Deportefety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

  • Surface-enhanced laser desorption/ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node-negative breast cancer tumors.
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Régine Deporte-fety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

Gabriel Ricolleau - One of the best experts on this subject based on the ideXlab platform.

  • surface enhanced laser desorption ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node negative breast cancer tumors
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Regine Deportefety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.

  • Surface-enhanced laser desorption/ionization time of fLight mass spectrometry protein profiling identifies ubiquitin and Ferritin Light Chain as prognostic biomarkers in node-negative breast cancer tumors.
    Proteomics, 2006
    Co-Authors: Gabriel Ricolleau, Mariepierre Joalland, Laurence Lode, Catherine Charbonnel, Sabine Jourdain, Mario Campone, Delphine Loussouarn, Ralf Bogumil, Stephane Minvielle, Régine Deporte-fety
    Abstract:

    Novel prognostic biomarkers are imperatively needed to help direct treatment decisions by typing subgroups of node-negative breast cancer patients. The current study has used a proteomic approach of SELDI-TOF-MS screening to identify differentially cytosolic expressed proteins with a prognostic impact in 30 node-negative breast cancer patients with no relapse versus 30 patients with metastatic relapse. The data analysis took into account 73 peaks, among which 2 proved, by means of univariate Cox regression, to have a good cumulative prognostic-informative power. Repeated random sampling (n = 500) was performed to ensure the reliability of the peaks. Optimized thresholds were then computed to use both peaks as risk factors and, adding them to the St. Gallen ones, improve the prognostic classification of node-negative breast cancer patients. Identification of ubiquitin and Ferritin Light Chain (FLC), corresponding to the two peaks of interest, was obtained using ProteinChip LDI-Qq-TOF-MS. Differential expression of the two proteins was further confirmed by Western blotting analyses and immunohistochemistry. SELDI-TOF-MS protein profiling clearly showed that a high level of cytosolic ubiquitin and/or a low level of FLC were associated with a good prognosis in breast cancer.